SELLAS Life Sciences Group Inc(SLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.21 | Insider Own | 1.11% | Shs Outstand | 201.9M | Perf Week | -14.5% |
| Market Cap | 2.10B | Forward P/E | - | EPS next Y | 53.66% | Insider Trans | - | Shs Float | 199.7M | Perf Month | -9.82% |
| Enterprise Value | 1.96B | PEG | - | EPS next Q | -0.05 | Inst Own | 36.81% | Short Float | 26.92% | Perf Quarter | 0.87% |
| Income | -0.03B | P/S | - | EPS this Y | 18% | Inst Trans | 11.28% | Short Ratio | 8.45 | Perf Half Y | 122.27% |
| Sales | 0.00B | P/B | 15.23 | EPS next 5Y | - | ROA | -36.54% | Short Interest | 53.76M | Perf YTD | 175.33% |
| Book/sh | 0.68 | P/C | 15.14 | EPS past 3/5Y | 51.28% 34.92% | ROE | -39.63% | 52W High | -34.62% ($15.88) | Perf Year | 419% |
| Cash/sh | 0.69 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.55% | 52W Low | 646.76% ($1.39) | Perf 3Y | 1009.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.38% | Gross Margin | - | Volatility(W/M) | 11.58% 8.75% | Perf 5Y | 19.59% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.02 | Perf 10Y | -99.86% |
| Dividend Ex-Date | 2011/3/24 | Quick Ratio | 18.83 | EPS Q/Q | 24.18% | Profit Margin | - | RSI (14) | 42.25 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.83 | Sales Q/Q | - | SMA20 | -9.42% ($11.46) | Beta | 2.7 | Target Price | $32.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -15.65% ($12.31) | Rel Volume | 3.73 | Prev Close | $12.17 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -11.11% - | SMA200 | 21.91% ($8.51) | Avg Volume(3M) | 6.37M | Price | $10.38 |
| IPO | 2008/3/12 | Option/Short | Yes/Yes | Trades | 68439 | Volume | 23,772,631 | Change | -14.71% |
🧬 Cellectar Life Sciences (SLS) is a late-stage clinical biopharmaceutical company developing therapies that target both blood cancers and solid tumors. Its core pipeline includes galinpepimut-S (GPS), an immunotherapy vaccine targeting acute myeloid leukemia, and SLS009, a targeted inhibitor. The company is focused on drug development, advancing clinical programs in oncology areas with significant unmet medical needs.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded more than usual. That is 373% of its average volume.
SLS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.0% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +19.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #99 of 594 in the industry
Based on market cap of $2B.
PVLA#96 Palvella Therapeutics Inc $2B PER - 
LKFT#97 Lakefront Biotherapeutics NV ADR $2B PER 3.0 
VCEL#98 Vericel Corp $2B PER 88.9 SLS#99 SELLAS Life Sciences Group Inc $2B PER - 
ZYME#100 Zymeworks BC Inc $2B PER - 
FAQ
What kind of company is SLS?
SLS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLS?
The market cap of SLS is approximately $2.1B, ranking 2,029 within its sector.
What is the 52-week high and low for SLS?
SLS has recorded a 52-week high of $15.88 and a low of $1.39.
